Jazz Pharmaceuticals plc stock jumped on positive Ziihera trial results. Click for my updated look at JAZZ stock and see why I am downgrading it.

Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with ...

Investing.com -- Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock rose 2.4% on Monday after CEO Allen Baharaff issued a shareholder letter highlighting the company’s financial position and clinical ...

LYMPHIR is the first FDA-approved systemic therapy for CTCL in more than seven years. According to the company, the therapy demonstrated a 36.2% objective response rate in its pivotal trial, with 84% ...

Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) just unveiled an update. Jacobio Pharmaceuticals Group Co., Ltd. announced that its ...

In connection with the proposed offering, Olema expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock Olema is offering ...

Roche on Tuesday said that lidERA is the first phase 3 trial of a selective oestrogen receptor degrader (SERD) to demonstrate a significant benefit in the adjuvant setting. The majority of breast ...

Merck & Co. MRK and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. Merck is a pharmaceutical conglomerate with a strong oncology franchise, ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

Royalty Pharma plc (NASDAQ:RPRX) is one of the most undervalued and overlooked large-cap stocks. On August 25, Royalty Pharma plc (NASDAQ:RPRX) said it bought royalty rights to Amgen’s cancer drug ...

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.